Friendswood, Texas, USA, April 21, 2026

In a significant development in precision diagnostics for oncology, Castle Biosciences, Inc. has announced new clinical data demonstrating the effectiveness of its DecisionDx®-Melanoma test in identifying patients with early-stage melanoma who are at higher risk of recurrence and poor outcomes. The findings, set to be presented at the European Congress of Dermato-Oncology (EADO) and the American College of Mohs Surgery (ACMS) Annual Meeting, highlight the growing importance of molecular diagnostics in improving cancer risk stratification and personalized treatment decisions. This breakthrough reinforces the clinical value of integrating gene expression profiling (GEP) with traditional staging systems to enhance prognostic accuracy and patient management strategies.

DecisionDx-Melanoma Enhances Early Risk Identification

The DecisionDx-Melanoma test, a 31-gene expression profile (GEP) assay, is designed to analyze tumor biology and provide personalized risk assessments for patients with stage I–III cutaneous melanoma. New multi-center clinical data involving 1,817 patients demonstrate that the test significantly improves 5-year recurrence risk prediction when used alongside the traditional American Joint Committee on Cancer (AJCC) staging system.

Importantly, the test identifies biologically high-risk patients within early-stage disease, including those with thin tumors (stage I–IIA), whose risk profiles may otherwise be underestimated using conventional staging alone. These patients were shown to have recurrence rates comparable to those seen in more advanced stages, underscoring the importance of early and accurate risk detection in guiding clinical decisions such as surveillance intensity and treatment escalation.

Clinical Utility in Personalized Melanoma Management

Advertisement

cGxPJobs Banner

The data further demonstrate that DecisionDx-Melanoma provides clinically actionable insights that align with National Comprehensive Cancer Network (NCCN) guidelines, supporting decisions related to sentinel lymph node biopsy (SLNB) and follow-up care. In addition to clinical trial data, population-based analysis using SEER registry data revealed that the test can identify high-risk patients even within T1 melanoma categories, which are typically considered low risk.

These patients exhibited significantly lower 5-year melanoma-specific survival rates, highlighting the test’s ability to uncover hidden risk profiles that could otherwise go undetected. By combining molecular data with clinicopathologic features, DecisionDx-Melanoma enables clinicians to make more informed, risk-aligned management decisions, ultimately improving patient outcomes while avoiding unnecessary interventions in low-risk cases.

Advancing Precision Diagnostics in Oncology

Castle Biosciences’ latest findings underscore the broader shift toward precision medicine and personalized oncology, where diagnostic tools play a critical role in tailoring treatment strategies. With over 58 peer-reviewed publications and validation across more than 10,000 patient samples, DecisionDx-Melanoma has emerged as a leading tool in melanoma prognostics, having been ordered more than 230,000 times since its launch.

The company’s focus on developing clinically validated, molecular diagnostic solutions reflects a growing demand for tools that can enhance risk stratification, improve survival outcomes, and optimize healthcare resource utilization. As melanoma incidence continues to rise globally, innovations like DecisionDx-Melanoma are poised to transform the standard of care by enabling earlier intervention and more precise treatment pathways.

Overall, Castle Biosciences’ presentation at leading oncology conferences marks a pivotal step in advancing molecular diagnostics for melanoma, offering clinicians a powerful tool to better identify high-risk patients and deliver personalized, data-driven care. This innovation highlights the critical role of genomic testing in modern oncology, paving the way for improved patient outcomes and more efficient healthcare delivery.

Source: Castle Biosciences press release